K Lin1, B D Nguyen, D S Ettinger, B B Chin. 1. Department of Radiology and Radiological Sciences, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA.
Abstract
PURPOSE: This report illustrates the potential diagnostic and therapeutic utility of somatostatin receptor scintigraphy and therapy with somatostatin. METHODS: In-111 pentetreotide (In-111 octreotide), a somatostatin analog, was used to define the receptor status and the extent of disease in a case of malignant thymoma. RESULTS: Subsequent treatment with nonradioactive somatostatin inhibited tumor growth. CONCLUSION: In-111 octreotide may be useful to define tumor receptor status and may provide prognostic information useful in determining subsequent therapy.
PURPOSE: This report illustrates the potential diagnostic and therapeutic utility of somatostatin receptor scintigraphy and therapy with somatostatin. METHODS: In-111 pentetreotide (In-111 octreotide), a somatostatin analog, was used to define the receptor status and the extent of disease in a case of malignant thymoma. RESULTS: Subsequent treatment with nonradioactive somatostatin inhibited tumor growth. CONCLUSION:In-111 octreotide may be useful to define tumor receptor status and may provide prognostic information useful in determining subsequent therapy.
Authors: P Ameri; F Gatto; M Arvigo; G Villa; E Resmini; F Minuto; G Murialdo; D Ferone Journal: J Endocrinol Invest Date: 2007-11 Impact factor: 4.256
Authors: D Ferone; R Pivonello; D J Kwekkeboom; F Gatto; P Ameri; A Colao; R R de Krijger; F Minuto; S W J Lamberts; P M van Hagen; L J Hofland Journal: J Endocrinol Invest Date: 2011-07-13 Impact factor: 4.256
Authors: D Ferone; D J Kwekkeboom; R Pivonello; A Bogers ADColao; S W Lamberts; P M van Hagen; L J Hofland Journal: J Endocrinol Invest Date: 2001 Jul-Aug Impact factor: 4.256
Authors: Z R Gao; C Kornblum; S Flacke; T Logvinski; M Yüksel; R An; T Klockgether; H J Biersack; S Ezziddin Journal: Neurol Sci Date: 2007-08-10 Impact factor: 3.307